60 Degrees Pharma withdraws mid-stage study application for COVID drug

The decision follows FDA's comments regarding the study design, the company said, adding that it plans to resubmit a revised application later in the year after a feasibility assessment. Tafenoquine, branded as Arakoda, was approved in the U.S. for prevention of malaria in 2018.